J&J, Gilead hepatitis drugs impress in combo study, but will they be tested further?
This article was originally published in Scrip
Johnson & Johnson drug partner Medivir disclosed interim Phase II study results showing that the companies’ experimental hepatitis C drug simeprevir was highly effective for hard to treat patients when combined with Gilead Sciences’ therapy sofosbuvir.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.